Related Experiment Videos
A pitfall to avoid when starting a patient on transdermal fentanyl
1Department of Palliative Care, Prince of Wales Hospital, New South Wales. jamesalvinlow@hotmail.com
Australian Family Physician
|January 5, 2001
Summary
When switching from oral morphine to transdermal fentanyl, careful dose titration is crucial. This ensures patient safety and avoids potential fentanyl toxicity during cancer pain management.
Area of Science:
- Oncology
- Pharmacology
- Pain Management
Background:
- Advanced ovarian carcinoma presents complex pain management challenges.
- Transitioning between opioid analgesics requires careful consideration of pharmacokinetic differences.
Observation:
- A patient receiving transdermal fentanyl post-oral morphine experienced fentanyl toxicity.
- This event occurred during the initiation phase of transdermal fentanyl therapy.
Findings:
- Inadequate dose adjustment during the switch from oral morphine to transdermal fentanyl can lead to opioid toxicity.
- Transdermal fentanyl offers effective cancer pain control but necessitates cautious initiation.
Implications:
- Implementing standardized protocols for opioid conversion is essential.
- Enhanced patient monitoring during transitions in opioid therapy can prevent adverse events.
- This case highlights the critical need for individualized dosing and close observation in palliative care.